Lazard Sees More Deals in $100 Billion Health-Care Recovery

Lazard Sees More Deals in $100 Billion Health-Care Recovery

A sharp recovery in health-care dealmaking will quicken as large pharmaceutical companies chase new treatments through acquisitions, according to one of Lazard Ltd.'s senior investment bankers covering the sector.Since the start of August, the value of health-care deals globally has more than doubled year-on-year to $102 billion, according to data compiled by Bloomberg. That's thanks to multibillion-dollar deals from the likes of French pharmaceutical group Sanofi to U.S.-based Gilead Sciences Inc.